Portage Biotech Inc
NASDAQ:ATON
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Spiritus Mundi PLC
LSE:SPMU
|
UK |
|
BHG Retail REIT
SGX:BMGU
|
SG |
|
Audacia SA
PAR:ALAUD
|
FR |
|
A
|
Actions Technology Co Ltd
SSE:688049
|
CN |
|
Ridgepost Capital Inc
NYSE:RPC
|
US |
|
Modern Land (China) Co Ltd
HKEX:1107
|
CN |
|
Rapid Nutrition PLC
PAR:ALRPD
|
UK |
|
Tix Corp
OTC:TIXC
|
US |
Portage Biotech Inc
Other Items
Portage Biotech Inc
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Portage Biotech Inc
NASDAQ:ATON
|
Other Items
-$50k
|
CAGR 3-Years
57%
|
CAGR 5-Years
43%
|
CAGR 10-Years
30%
|
|
Portage Biotech Inc
Glance View
Portage Biotech, Inc. is a biotechnology company, which engages in the research and development of immuno-oncology therapies for patients with cancer. The firm is engaged in advancing therapies to improve long-term treatment, response, and quality of life in patients with cancers. The Company’s access to technologies coupled with biological mechanisms enables the identification of clinical therapies and product development strategies, which accelerate these medicines through the translational pipeline. Its adenosine antagonist platform include PORT-9 and PORT-8. PORT-9 and PORT-8 are in the preclinical stage. Its PORT-8 is a dual inhibitor of adenosine receptors 2A and 2B (A2A/A2B) to address solid tumors. Its PORT-9 is an A2B antagonist designed to treat colorectal and gastrointestinal cancers. Its iNKT Engager platform includes PORT- 3, which is in Phase I.
See Also
What is Portage Biotech Inc's Other Items?
Other Items
-50k
USD
Based on the financial report for Sep 30, 2025, Portage Biotech Inc's Other Items amounts to -50k USD.
What is Portage Biotech Inc's Other Items growth rate?
Other Items CAGR 10Y
30%
The average annual Other Items growth rates for Portage Biotech Inc have been 57% over the past three years , 43% over the past five years , and 30% over the past ten years .
